Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
54.830USD
+2.410+4.60%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
5.29BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+4.60%
5 Days
+6.20%
1 Month
+7.05%
6 Months
+0.46%
Year to Date
+4.56%
1 Year
+53.93%
TradingKey Stock Score of CRISPR Therapeutics AG
Currency: USD Updated: 2026-05-08Key Insights
CRISPR Therapeutics AG's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 87 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.22.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CRISPR Therapeutics AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CRISPR Therapeutics AG Highlights
StrengthsRisks
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.51M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.51M.
Overvalued
The company’s latest PE is -8.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.20M shares, decreasing 12.26% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.54K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
80.309
Target Price
+53.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CRISPR Therapeutics AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CRISPR Therapeutics AG Info
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Ticker SymbolCRSP
CompanyCRISPR Therapeutics AG
CEOKulkarni (Samarth)
Websitehttps://crisprtx.com/
Related Instruments
-2.75%
-0.53%
-0.67%
+0.54%
+0.20%
-0.82%
+0.79%
-2.04%
+0.61%
-1.48%
-0.14%
+1.13%
+0.30%
-0.20%
-2.42%
+0.82%
0.00%
-1.05%
-0.65%
-0.86%Popular Instruments
96.758
+4.565 (+4.95%)
293.320
+5.817 (+2.02%)
215.200
+3.717 (+1.76%)
4695.420
-18.860 (-0.40%)
480.000
+16.095 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.160 (+15.49%)
400.800
+2.723 (+0.68%)
81472.040
+767.160 (+0.95%)
428.350
+16.560 (+4.02%)
